Tampa、FLにおける転移性癌の臨床試験
Tampaとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する29件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Tampa
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- Moffitt Cancer Center, Tampa
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
被験者募集中第1相
- ALX Center 7, Tampa
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
被験者募集中第2/3相
- Moffitt Cancer Center, Tampa
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
被験者募集中第1相
- Moffitt Cancer Center, Tampa
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
被験者募集中第2相
- Moffitt Cancer Center, Tampa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Florida Cancer Specialists, Tampa
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Moffitt, Tampa
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Moffitt Cancer Center, Tampa
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Moffitt Cancer Center and Research Institute, Tampa
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
被験者募集中第1/2相
- Moffitt Cancer Center, Tampa
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Tampa
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Moffitt Cancer Center, Tampa
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Tampa
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #128, Tampa
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
被験者募集中第1相
- Moffitt Cancer Center, Tampa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- Moffitt Cancer Center, Tampa
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #8, Tampa
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
被験者募集中第3相
- Moffitt Cancer Center, Tampa
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
被験者募集中第2相
- James A. Haley Veterans Administration Hospital, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
被験者募集中第1相
- Moffitt Cancer Center, Tampa
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Lee Moffitt Cancer Center, Tampa
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
被験者募集中第1相
- Moffitt Cancer Center, Tampa
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Moffitt Cancer Center, Tampa
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
被験者募集中第2/3相
- Moffitt Cancer Center, Tampa
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- Moffitt Cancer Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Tampa
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
被験者募集中第1相
- H. Lee Moffitt Cancer Center and Research Institute, Tampa
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
Tampaにおける他の研究
- 非小細胞肺癌51件の研究
- 乳がん43件の研究
- がん（全種類）39件の研究
- 大腸癌34件の研究
- 急性骨髄性白血病29件の研究
- 肺がん29件の研究
- 膵臓がん26件の研究
- 卵巣がん21件の研究
- 悪性黒色腫19件の研究
- 骨髄異形成症候群19件の研究
- 前立腺がん18件の研究
- 心不全18件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。